Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions

Affiliations

Comment

Dennis C Sgroi et al. J Clin Oncol. 2016.

. 2016 Nov 10;34(32):3941-3942.

doi: 10.1200/JCO.2016.67.2949.

¹ Dennis C. Sgroi, Massachusetts General Hospital, Charlestown and Boston, MA; and Adam Brufsky, University of Pittsburgh Medical Center, Pittsburgh, PA.

No abstract available

Comment in

Reply to D.C. Sgroi et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al.
Harris LN, Ismaila N, McShane LM, Andre F. Harris LN, et al. J Clin Oncol. 2016 Nov 10;34(32):3946-3948. doi: 10.1200/JCO.2016.68.7020. J Clin Oncol. 2016. PMID: 27551123 No abstract available.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Harris LN, et al. J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858339 Free PMC article. Review.